tbuckley/cabot-search huggingface dataset:
Effectiveness of online tailored advice to prevent running-related injuries and promote preventive behaviour in Dutch trail runners: a pragmatic randomised controlled trial
Authors: Luiz Carlos Hespanhol, Willem van Mechelen, Evert Verhagen
Journal: British Journal of Sports Medicine (2017)

Background Trail running is popular worldwide, but there is no preventive intervention for running-related injury (RRI). Aim To evaluate the effectiveness of adding online tailored advice ( TrailS 6 ) to general advice on (1) the prevention of RRIs and (2) the determinants and actual preventive behaviour in Dutch trail runners. Methods Two-arm randomised controlled trial over 6 months. 232 trail runners were randomly assigned to an intervention or control group. All participants received online general advice on RRI prevention 1 week after baseline. Every 2 weeks, participants in the intervention group received specific advice tailored to their RRI status. The control group received no further intervention. Bayesian mixed models were used to analyse the data. Results Trail runners in the intervention group sustained 13% fewer RRIs compared with those in the control group after 6 months of follow-up (absolute risk difference −13.1%, 95% Bayesian highest posterior credible interval (95% BCI) −23.3 to −3.1). A preventive benefit was observed in one out of eight trail runners who had received the online tailored advice for 6 months (number needed to treat 8, 95% BCI 3 to 22). No significant between-group difference was observed on the determinants and actual preventive behaviours. Conclusions Online tailored advice prevented RRIs among Dutch trail runners. Therefore, online tailored advice may be used as a preventive component in multicomponent RRI prevention programmes. No effect was observed on determinants and actual preventive behaviours. Trial registration number The Netherlands National Trial Register (NTR5431).
The Waiting Room
Authors: Roger Sippl
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFκB
Authors: Anna Dorota Chorzalska, John Morgan, Diana Olguta Treaba, Adam J Olszewski, Nathan Kingston, Yan Cheng, Kara Lombardo, Christoph Schorl, Xiaoqing Yu, Roberta Zini, Annalisa Pacilli, Alexander Tepper, Anita Hryniewicz-Jankowska, Ting Zhao, Elena Oancea, John L Reagan, Eric S Winer, Leszek Kotula, Peter J Quesenberry, Philip Gruppuso, Rossella Manfredini, Alessandro M. Vannucchi, Patrycja M Dubielecka
Journal: Blood (2016)
Vital Signs: Recent Trends in Stroke Death Rates — United States, 2000–2015
Authors: Quanhe Yang, Xin Tong, Linda Schieb, Adam Vaughan, Cathleen Gillespie, Jennifer L. Wiltz, Sallyann Coleman King, Erika Odom, Robert Merritt, Yuling Hong, Mary G. George
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Introduction:The prominent decline in U.S. stroke death rates observed for more than 4 decades has slowed in recent years.CDC examined trends and patterns in recent stroke death rates among U.S. adults aged ≥35 years by age, sex, race/ethnicity, state, and census region.Methods: Trends in the rates of stroke as the underlying cause of death during 2000-2015 were analyzed using data from the National Vital Statistics System.Joinpoint software was used to identify trends in stroke death rates, and the excess number of stroke deaths resulting from unfavorable changes in trends was estimated.Results: Among adults aged ≥35 years, age-standardized stroke death rates declined 38%, from 118.4 per 100,000 persons in 2000 to 73.3 per 100,000 persons in 2015.The annual percent change (APC) in stroke death rates changed from 2000 to 2015, from a 3.4% decrease per year during 2000-2003, to a 6.6% decrease per year during 2003-2006, a 3.1% decrease per year during 2006-2013, and a 2.5% (nonsignificant) increase per year during 2013-2015.The last trend segment indicated a reversal from a decrease to a statistically significant increase among Hispanics (APC = 5.8%) and among persons in the South Census Region (APC = 4.2%).Declines in stroke death rates failed to continue in 38 states, and during 2013-2015, an estimated 32,593 excess stroke deaths might not have occurred if the previous rate of decline could have been sustained. Conclusions and Implications for Public Health Practice:Prior declines in stroke death rates have not continued in recent years, and substantial variations exist in timing and magnitude of change by demographic and geographic characteristics.These findings suggest the importance of strategically identifying opportunities for prevention and intervening in vulnerable populations, especially because effective and underused interventions to prevent stroke incidence and death are known to exist.
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
Authors: Hagop M. Kantarjian, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, Hanna Jean Khoury, Moshe Talpaz, Michele Baccarani, Stephanie Lustgarten, Sergio Santillana, Francois Guilhot, Michael W.N. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Jorge E. Cortes
Journal: Journal of Clinical Oncology (2017)

7012 Background: The tyrosine kinase inhibitor (TKI) ponatinib has potent activity against native and mutant BCR-ABL1 and is approved for use in pts with relapsed/intolerant CML or Ph+ ALL, or with BCR-ABL1/T315I. Methods: In the pivotal PACE study (NCT01207440), ponatinib (starting dose 45 mg/d) was assessed in pts with CML or Ph+ ALL resistant/intolerant to dasatinib or nilotinib, or with T315I. In Oct ’13, dose reductions were implemented due to observed arterial occlusive events (AOEs). Efficacy and safety at 5 yrs (data as of 3 Oct ’16) for CP-CML pts are reported. Results: Of 270 CP-CML pts in the safety population, 60% received ≥3 prior TKIs. At initiation of study closure, 99 pts were ongoing; among these pts, minimum follow-up was 52 months, and most (78%) had 15 mg/d as their last dose. In all CP-CML pts (n = 267, efficacy evaluable), cumulative response rates were: MCyR, 60%; CCyR, 54%; MMR, 40%; and MR 4.5 , 24%. Among pts who achieved MCyR (n = 148) or MMR (n = 108), the Kaplan-Meier (KM) estimated probability of remaining in response at 5 yrs was 74% (95% CI, 62 – 83) and 61% (95% CI, 51 – 70), respectively. Regardless of dose reduction in Oct ’13, maintenance of response was high (Table). KM estimated 5-yr rate for PFS/OS was 49%/77%. TEAEs in ≥45% of CP-CML pts were rash 47%, abdominal pain 46%, and thrombocytopenia 46%. Most newly occurring AEs were observed within the first year. The incidence of any AOEs/serious AOEs for CP-CML pts was 29%/23%. Among CP-CML pts with no prior AOEs who had a prospective dose reduction, 17% (11/63) had a first AOE occurring after Oct ‘13. Conclusions: Long-term (5-yr) results from PACE demonstrate that ponatinib continues to show clinical benefit, irrespective of dose reductions, with deep and lasting responses in heavily pretreated CP-CML pts. Safety results were consistent with the safety profile across the ponatinib clinical program. Clinical trial information: NCT01207440. [Table: see text]
ナノグラフェン媒介in vivo蛍光イメージングと腫瘍の二峰性光線力学および光熱破壊【Powered by NICT】
Authors: Kalluru Poliraju, Vankayala Raviraj, Chiang Chi-Shiun, Hwang Kuo Chu
Journal: Biomaterials (2016)
Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis
Authors: Asawari Korde, Lei Jin, Jian-ge Zhang, Anuradha Ramaswamy, Buqu Hu, Saeed Kolahian, Brenda Juan Guardela, Jose Herazo-Maya, Jill M. Siegfried, Laura Stabile, Margaret A. Pisani, Roy S. Herbst, Naftali Kaminski, Jack A. Elias, Jonathan T. Puchalski, Shervin S. Takyar
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Vascular endothelial growth factor down-regulates microRNA-1 (miR-1) in the lung endothelium, and endothelial cells play a critical role in tumor progression and angiogenesis. To examine the clinical significance of miR-1 in non-small cell lung cancer (NSCLC) and its specific role in tumor endothelium. miR-1 levels were measured by Taqman assay. Endothelial cells were isolated by magnetic sorting. We used vascular endothelial cadherin promoter to create a vascular-specific miR-1 lentiviral vector and an inducible transgenic mouse. KRASG12D mut/Trp53-/- (KP) mice, lung-specific vascular endothelial growth factor transgenic mice, Lewis lung carcinoma xenografts, and primary endothelial cells were used to test the effects of miR-1. In two cohorts of patients with NSCLC, miR-1 levels were lower in tumors than the cancer-free tissue. Tumor miR-1 levels correlated with the overall survival of patients with NSCLC. miR-1 levels were also lower in endothelial cells isolated from NSCLC tumors and tumor-bearing lungs of KP mouse model. We examined the significance of lower miR-1 levels by testing the effects of vascular-specific miR-1 overexpression. Vector-mediated delivery or transgenic overexpression of miR-1 in endothelial cells decreased tumor burden in KP mice, reduced the growth and vascularity of Lewis lung carcinoma xenografts, and decreased tracheal angiogenesis in vascular endothelial growth factor transgenic mice. In endothelial cells, miR-1 level was regulated through phosphoinositide 3-kinase and specifically controlled proliferation, de novo DNA synthesis, and ERK1/2 activation. Myeloproliferative leukemia oncogene was targeted by miR-1 in the lung endothelium and regulated tumor growth and angiogenesis. Endothelial miR-1 is down-regulated in NSCLC tumors and controls tumor progression and angiogenesis.
Glycan alterations on serum mucins in pancreatic cancer patients
Authors: Tingting Yue, Irwin Goldstein, Michael Hollingsworth, Randall Brand, Brian Haab
Journal: Cancer Research (2008)

5513   The carbohydrate structures on certain mucins are frequently altered in pancreatic cancer patients. A characterization of the variation in those structures over many cancer patients could be used to assess their diagnostic value and to identify possible functional relationships with disease. Using a novel method of profiling glycans on native proteins using antibody arrays, we characterized certain glycan levels on several mucins (MUC1, MUC5ac, MUC16) in the sera of pancreatic cancer patients (n = 23) and control subjects (n = 23). Probing the proteins with 22 different glycan binding lectins or antibodies revealed several groups of glycans that were elevated in cancer, including Lewis antigens, T/Tn antigens, and fucose groups. Glycan detection greatly improved the discrimination between cancer and control samples relative to detecting the glycoprotein alone. For example, at a threshold defining an 87% specificity (3/23 control samples above the threshold), 7/23 cancer patients (30% sensitivity) showed an elevation in the MUC5ac core protein (AUC=0.72), but 23/23 cancer patients (100% sensitivity) showed an elevation in WGA binding on MUC5ac (AUC=0.90). Using a panel of the top six glycan measurements, we detected all but one (96% sensitivity) at a 100% specificity, which was an improvement over the use of CA 19-9 alone. These data provide the first look at the variability in glycan structures between people and molecules and have revealed previously unknown associations with cancer. These results also validate the concept of using glycan detection for improved biomarker accuracy and highlight the advantage of this approach for that research.
Shrimp miR-S8 Suppresses the Stemness of Human Melanoma Stem-like Cells by Targeting the Transcription Factor YB-1
Authors: Fan Yang, Jun Wei, Song Zhang, Xiaobo Zhang
Journal: Cancer Research (2017)

Abstract Cross-species regulation of gene expression by microRNA is a possible untapped opportunity for miRNA-based therapy. In this study, we report a novel approach to ablate melanoma stem-like cells by targeting the transcription factor YB-1, which is significantly and selectively upregulated in these cells in melanoma. Silencing YB-1 expression was sufficient to significantly inhibit the stemness of melanoma stem-like cells. In exploring YB-1 targeting, we discovered that the shrimp microRNA miR-S8 could suppress human YB-1 expression in melanoma stem-like cells. Mechanistic investigations revealed that miR-S8 recognized the 3′UTR of YB-1 mRNA and mediated its degradation. In tumor cell and xenograft experiments, miR-S8 suppressed the tumorigenic capacity of melanoma stem-like cells by targeting human YB-1. Overall, our results illuminated a novel aspect of miRNA-mediated cross-species gene expression and its use in regulating cancer stem-like cells. Cancer Res; 77(20); 5543–53. ©2017 AACR.
Detection of Non–FDG-Avid Residual Sinonasal Malignant Melanoma in the Skull Base With 11C-Choline PET and Contrast-Enhanced MRI
Authors: Chunxia Qin, Fan Hu, Maher Mohamad Rajab Arnous, Xiaoli Lan
Journal: Clinical Nuclear Medicine (2017)

Abstract Primary sinonasal melanoma is a rare disease. We present a case of melanoma in sinuses without abnormal 18 F-FDG activity anywhere in the scanned portion of the body. In further assessment, 11 C-choline PET/CT revealed high activity in the paranasal sinuses, skull base, and adjacent brain, in agreement with the high signal on contrast-enhanced T1-weighted MRI scan, which suggested the residual tumor.
Mistakes Were Made (by Me)
Authors: Reza Manesh
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
PD-L1 Is up-Regulated By EBV-Driven LMP1 through NF-κb Pathway and Correlates with Poor Prognosis in Natural Killer/T-Cell Lymphoma
Authors: Xi-Wen Bi, Hua Wang, Wen-Wen Zhang, Zhongjun Xia, Yu-jing Zhang, Liang Wang
Journal: Blood (2016)
Difference of Short-term and Long-term Morbidity in Patients with Non-valvular Atrial Fibrillation: Analysis from Shinken Database 2004-2013
Authors: Suzuki Shinya, Otsuka Takayuki, Sagara Koichi, Yagi Naoharu, Arita Takuto, Kinjo Taiki, Numao Yoshimi, Senba Hiroaki, Kanoh Hiroto, Matsuno Shunsuke, Katoh Yuko, Takai Hideaki, Uejima Tokuhisa, Oikawa Yuji, Nagashima Kazuyuki, Kirigaya Hajime, Kunihara Takashi, Yajima Junji, Sawada Hitoshi, Aizawa Tadanori, Yamashita Takeshi
Journal: Circulation (2016)
Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant
Authors: Edward Cantu, Joshua M. Diamond, Yoshikazu Suzuki, Jared Lasky, Christian Schaufler, Brian Lim, Rupal Shah, Mary Porteous, David J. Lederer, Steven M. Kawut, Scott M. Palmer, Laurie D. Snyder, Matthew G. Hartwig, Vibha N. Lama, Sangeeta Bhorade, Christian Bermudez, Maria Crespo, John McDyer, Keith Wille, Jonathan Orens, Pali D. Shah, Ann Weinacker, David Weill, David Wilkes, David Roe, Chadi Hage, Lorraine B. Ware, Scarlett L. Bellamy, Jason D. Christie
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Primary graft dysfunction (PGD) is a form of acute lung injury that occurs after lung transplantation. The definition of PGD was standardized in 2005. Since that time, clinical practice has evolved, and this definition is increasingly used as a primary endpoint for clinical trials; therefore, validation is warranted.
急性冠症候群患者における循環アディポネクチン値と冠状動脈プラーク:JAPAN‐ACSサブグループ分析
Authors: Ohashi Taiki, Shibata Rei, Ishii Hideki, Ichimiya Satoshi, Kanashiro Masaaki, Ozaki Yukio, Kimura Takeshi, Morimoto Takeshi, Daida Hiroyuki, Murohara Toyoaki, Matsuzaki Masunori
Journal: Circulation (2009)
AB0881 Assessment of sudomotor function in patient with gout
Authors: JW Lee, HO Kim, S Lee, G Kim
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Sodorimetry is a non-invasive device measures sweat gland dysfunction using electrochemical skin conductance (ESC) of hands and feet and is useful for assessing peripheral small fiber nerve function. Little is known about the dysfunction of peripheral small fiber nerve in patients with gout. <h3>Objectives</h3> To evaluate the prevalence and characteristics of small fiber neuropath (SFN) in patients with gout compared with a healty control group and to identify factors associated with SFN in gout. <h3>Methods</h3> 80 male patients with well symtom controlled gout (age: 58±12) and 80 healthy controls were enrolled. Each patient was required to fast over 8 hours before blood samples. Serum fasting glucose, fasting insulin, uric acid, serum 25-(OH) D, lipid profiles, Creatinine (Cr) and r-GTP were measured. Body mass index (BMI) and Homeostatic model assessment insulin resistance (HOMA IR) were calculated. Patients already diagnosed with hypertension and diabetes were excluded. <h3>Results</h3> The mean feet and hands ESC were significantly lower in the gout group than the control group. Mean Hands ESC was irrelevant to age, BMI, fasting glucose and insulin, HOMA-IR, vit D, uric acid, Cr, and lipids. However, mean feet ESC showed significant correlation with fasting glucose (r=-0.7, p&lt;0.01) and HOMA-IR (r=-0.25, p=0.03). <h3>Conclusions</h3> Sudomotor function was significantly lower in patients with gout than the control group. Mean feet ESC was correlated with fasting glucose and insulin resistance in patients with gout. These results suggest that dysfunction of SFN in gout patients is associated with insulin resistance and impaired fasting glucose. <h3>Disclosure of Interest</h3> None declared
AB0832 Effect of long-term proton pump inhibitors on bone mineral density
Authors: H Romdhane, M Cheikh, H Ben Nejma, R Ennaifer, N Bel Hadj
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Proton pump inhibitors (PPI) are widespread nowadays. Recent concerns have emerged about possible bone complications of long-term use of PPIs, such as low bone mineral density (BMD) and an increased risk of fractures. <h3>Objectives</h3> The aim of our study was to evaluate the effect of long-term use of PPIs on bone by measuring the BMD in order to estimate the frequency of osteopenia and osteoporosis, and to determine the risk factors associated to this complication. <h3>Methods</h3> It was a prospective study including consecutive patients who where taking proton pump inhibitors for at least one year. In all patients we realized a bone densitometry in order to evaluate the bone strength and we calculated the FRAX score to estimate the risk of osteoporotic fracture at ten years. <h3>Results</h3> We included 52 patients. The mean age was 49,5 years old. The male-female ratio M/F was 0,48. At least three risk factors were found in more than 50% of the population. The calculated daily calcium intake was insufficient in 94% of the patients. The mean duration of PPIs intake was 45 months. The most frequent indication was gastro esophageal reflux disease (75%). The PPI prescription was appropriate in 94% of the cases. The prevalence of osteopenia and osteoporosis was respectively 52% and 19%. The predictive factors of low BMD were an age ≥50 years old (p=0,03), the menopause (p&lt;0,0001), a calcium intake ≤550 mg/day (p&lt;0,038), and a PPI use duration ≥30 months (p&lt;0,006). The multivariate study could not be undertaken because of co linearity of the factors. <h3>Conclusions</h3> The long term PPI use is associated to the risk of bone complications, especially among patients at risk for osteoporosis. It seems reasonable to be more vigilant in prescribing PPIs and use lowest effective dose for patients with appropriate indications, and to screen these complications if necessary. <h3>Disclosure of Interest</h3> None declared
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma
Authors: John P. Leonard, Kathryn S. Kolibaba, James A. Reeves, Anil Tulpule, Ian W. Flinn, Tatjana Kolevska, Robert Robles, Christopher R. Flowers, Robert Collins, Nicholas J. DiBella, Steven W. Papish, Parameswaran Venugopal, Andrew Horodner, Amir Tabatabai, Julio Hajdenberg, Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, Dixie-Lee Esseltine, Sven de Vos
Journal: Journal of Clinical Oncology (2017)

Purpose To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods After real-time determination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were randomly assigned (1:1; stratified by International Prognostic Index [IPI] score) to six 21-day cycles of standard R-CHOP alone or R-CHOP plus bortezomib 1.3 mg/m2 intravenously on days 1 and 4 (VR-CHOP). The primary end point, progression-free survival (PFS), was evaluated in 183 patients with centrally confirmed non-GCB DLBCL who received one or more doses of study drug (91 R-CHOP, 92 VR-CHOP). Results After a median follow-up of 34 months, with 25% (R-CHOP) and 18% (VR-CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90% CI, 0.43 to 1.24) with VR-CHOP ( P = .611). Two-year PFS rates were 77.6% with R-CHOP and 82.0% with VR-CHOP; they were 65.1% versus 72.4% in patients with high-intermediate/high IPI (HR, 0.67; 90% CI, 0.34 to 1.29), and 90.0% versus 88.9% (HR, 0.85; 90% CI, 0.35 to 2.10) in patients with low/low-intermediate IPI. Overall response rate with R-CHOP and VR-CHOP was 98% and 96%, respectively. The overall survival HR was 0.75 (90% CI, 0.38 to 1.45); 2-year survival rates were 88.4% and 93.0%, respectively. In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade ≥ 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%). Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.